EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone

Intishar Kazi, Meghan J Chenoweth iD, Didier Jutras-Aswad, Keith Ahamad, M Eugenia Socias, Bernard Le Foll iD, Rachel F Tyndale iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3112 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Intishar Kazi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Centre for Addiction and Mental Health, Michael Smith Foundation for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical outcomes in people receiving opioid agonist therapies. Participants diagnosed with opioid use disorder, principally consisting of prescription opioids (licit or illicit), were randomized to methadone or buprenorphine/naloxone for 24 weeks of daily treatment (NCT03033732). Urine was collected at 12 biweekly study visits and analyzed for non‐treatment opioids. Variants in genes involved in methadone metabolism ( CYP2B6 , CYP2C19 , and CYP3A4 ), buprenorphine metabolism ( CYP3A4 and UGT2B7 ), and μ‐opioid receptor function ( OPRM1 ) were genotyped and analyzed for their association with the number of non‐treatment opioid‐free urine screens. Primary analyses focused on the last 12 weeks (6 study visits, post‐titration) of treatment among those reporting White ethnicity. Additional sensitivity and exploratory analyses were performed. Among methadone‐treated participants ( n = 52), the OPRM1 rs1799971 AA genotype (vs. G‐genotypes, i.e., having one or two G alleles) was associated with greater opioid‐free urine screens (incidence rate ratio = 5.24, 95% confidence interval (CI) = 2.43–11.26, P = 0.000023); longitudinal analyses showed a significant genotype‐by‐time interaction over the full 24 weeks (12 study visits, β = −0.28, 95% CI = −0.45 to −0.11, P = 0.0015). Exploratory analyses suggest an OPRM1 rs1799971 genotype effect on retention. No evidence of association was found between other genetic variants, including in metabolic variants, and non‐treatment opioid‐free urine screens in the methadone or buprenorphine/naloxone arms. Those with the OPRM1 rs1799971 G‐genotypes may have a poorer response to methadone maintenance treatment, an effect that persisted through 24 weeks of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersHumansMethadoneAnalgesics, OpioidPharmacogeneticsCytochrome P-450 CYP3ANarcotic AntagonistsBuprenorphine, Naloxone Drug CombinationOpiate Substitution Treatment

Substanzen

MethadoneAnalgesics, OpioidCytochrome P-450 CYP3ANarcotic AntagonistsBuprenorphine, Naloxone Drug CombinationBuprenorphine

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Research Centre, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
  • Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada.
  • British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.

ORCID-Profile: Meghan J Chenoweth, Bernard Le Foll, Rachel F Tyndale

Förderung

  • CIHR
  • Centre for Addiction and Mental Health
  • Michael Smith Foundation for Health Research
  • Canadian Institutes of Health Research

Zitieren

APA

Kazi, I., Chenoweth, M. J., Jutras-Aswad, D., Ahamad, K., Socias, M. E., Le Foll, B., & Tyndale, R. F. (2024). Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3112

Vancouver

Kazi I, Chenoweth MJ, Jutras-Aswad D, Ahamad K, Socias ME, Le Foll B, et al. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3112

BibTeX
@article{Kazi2024,
  author = {Kazi, Intishar and Chenoweth, Meghan J and Jutras-Aswad, Didier and Ahamad, Keith and Socias, M Eugenia and Le Foll, Bernard and Tyndale, Rachel F},
  title = {Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3112}
}
Kostenlos starten →